Get started
Author

Mitchell G. Kaye

Observed names: Kaye, Mitchell G., M Kaye, M. Kaye, M.G. Kaye, Mitchell G Kaye, Mitchell Kaye
OpenAlex ID: A5079875398
The Safety and Efficacy of Infliximab in Moderate to Severe Chronic Obstructive Pulmonary Disease
2007 · Stephen I. Rennard, Charles Fogarty, et al. · American Journal of Respiratory and Critical Care Medicine · 439
Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON
2018 · Bruno Crestani, John T Huggins, et al. · The Lancet Respiratory Medicine · 249
Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis
2023 · Toby M. Maher, Paul Ford, et al. · JAMA · 145
Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study
2019 · Toby M Maher, Susanne Stowasser, et al. · The Lancet Respiratory Medicine · 106
Feasibility and Value of Video-Assisted Thoracoscopic Surgery Wedge Excision of Small Pulmonary Nodules in Patients with Malignancy
2002 · Jim Burdine, Lyle D. Joyce, et al. · CHEST Journal · 74
Effects of Inhaled Leukotriene D4 and Platelet-activating Factor on Airway Reactivity in Normal Subjects
1990 · Mitchell G. Kaye, Lewis J. Smith · American Review of Respiratory Disease · 71
Effects of Nintedanib on Quantitative Lung Fibrosis Score in Idiopathic Pulmonary Fibrosis
2020 · Lisa Lancaster, Jonathan Goldin, et al. · The Open Respiratory Medicine Journal · 48
Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus tiotropium monotherapy in patients with COPD
2021 · Sandeep Bansal, Martin Anderson, et al. · npj Primary Care Respiratory Medicine · 26
PDF
Long-term treatment with nintedanib in patients with IPF: An update from INPULSIS®-ON
2016 · Bruno Crestani, Manuel Quaresma, et al. · 20
Effect of baseline emphysema on reduction in FVC decline with nintedanib in the INPULSIS™ trials
2015 · M Pfeifer, V Cottin, et al. · Pneumologie · 15
Interim analysis of nintedanib in an open-label extension of the INPULSIS® trials (INPULSIS®-ON)
2015 · Bruno Crestani, Takashi Ogura, et al. · 10
Long-term nintedanib treatment in idiopathic pulmonary fibrosis (IPF): new data from INPULSIS-ON
2017 · Bruno Crestani, Manuel Quaresma, et al. · 9
Key learnings from the INBUILD trial in patients with progressive pulmonary fibrosis
2024 · Isabel Mira-Avendano, Mitchell Kaye · Therapeutic Advances in Respiratory Disease · 3
P7 Interim analysis of nintedanib in an open-label extension of the INPULSIS® trials (INPULSIS®-ON)
2015 · B Crestani, T Ogura, et al. · Thorax · 3
Efficacy and Safety of Nintedanib in US and Non-US Patients With Idiopathic Pulmonary Fibrosis (IPF) in the INPULSIS Trials
2015 · John Huggins, Mitchell Kaye, et al. · CHEST Journal · 2
PDF
All-Cause Mortality by Subgroup in Patients with Chronic Obstructive Pulmonary Disease: Post Hoc Analysis of the IMPACT Trial
2021 · M.J. Mammen, T.F. Carr, et al. · 1
Long-term nintedanib treatment in idiopathic pulmonary fibrosis (IPF): final data from INPULSIS-ON
2018 · Bruno Crestani, Manuel Quaresma, et al. · 1
Long-term nintedanib treatment in idiopathic pulmonary fibrosis (IPF): new data from INPULSIS-ON
2018 · M Kreuter, B Crestani, et al. · Pneumologie · 1
Prognostic Power of the Metabolic Exercise Test Data Combined with Cardiac and Kidney Indexes (MECKI) Score in a Mixed American Cohort
2025 · A. Mallepally, K. Dandamudi, et al. · The Journal of Heart and Lung Transplantation
Author response for "Key learnings from the INBUILD trial in patients with progressive pulmonary fibrosis"
2024 · Isabel Mira-Avendano, Mitchell Kaye
Author response for "Key learnings from the INBUILD trial in patients with progressive pulmonary fibrosis"
2024 · Isabel Mira-Avendano, Mitchell Kaye
Author response for "Key learnings from the INBUILD trial in patients with progressive pulmonary fibrosis"
2023 · Isabel Mira-Avendano, Mitchell Kaye
Risk of All-Cause Mortality During and After Severe Exacerbations in Patients with Chronic Obstructive Pulmonary Disease (COPD): Post Hoc Analysis of the IMPACT Trial
2021 · M.J. Mammen, T.F. Carr, et al.
An Analysis of the IMPACT Trial Assessing Single-Inhaler Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus FF/VI and UMEC/VI Using a Composite Adverse Event Outcome in Patients with COPD
2021 · J.M. Wells, S.P. Bhatt, et al.
Single-inhaler Triple Therapy Fluticasone Furoate/umeclidinium/vilanterol Compared With Tiotropium Monotherapy in Copd: a Post Hoc Analysis by Airflow Limitation
2020 · Antonio Anzueto, Dany Obeid, et al. · CHEST Journal
PDF
Works count: 31
Citation count: 1,222
H-index: 10
I10-index: 11
Year
Topic
Type